Regulation of expression of interleukin 7 (IL-7) mRNA is aberrant in the leukemic subset of cells of chronic lymphocytic leukemia (CLL) patients. The entire coding sequence for IL-7 as well as an alternatively spliced IL-7 mRNA are transcribed in these leukemic cells. No IL-7 mRNA expression is detected in fresh peripheral blood mononuclear cells from normal individuals. Furthermore, the "normal" nonleukemic subsets of cells isolated from the same CLL patients also do not express IL-7 mRNA. The only subset of cells in which IL-7 mRNA is detected is the one that contains the leukemic cells themselves. The polymerase chain reaction was used to examine cytokine expression, and flow cytometry was used to purify the various subsets of peripheral blood mononuclear cells examined in these studies, as well as to examine IL-7 receptor expression. A proportion of the cells from the CLL patients express receptors that are capable of binding IL-7, whereas T cell-depleted normal cell preparations do not express receptors for IL-7 that are detectable with IL-7 fluorokines. The IL-7 receptor-bearing cells in CLL patients include a portion of leukemic cells and a fraction of the T cells, as well as some non-T, non-B cells. These findings suggest that IL-7 and IL-7 receptor expression in CLL may be relevant not only to growth regulation of the leukemic cells but to the immunological abnormalities that occur in the disease as well, possibly via the induction of inappropriate immune activity of IL-7 receptor-bearing cells.
C
hronic lymphocytic leukemia (CLL) 1 is a relatively stable, common form of leukemia, with >90% of B cell CLL cases resulting from the leukemic transformation and clonal expansion of a single B lymphocyte within the CD5 + subset (1) (2) (3) . CD5 + B cells account for 5-25% of circulating and splenic B lymphocytes in normal adults, and may serve as the first line of immunological defense against microorganisms in infants, as these cells frequently produce IgM antibodies that are polyspecific (4) (5) (6) (7) (8) (9) (10) (11) . CLL cells themselves are relatively mature B cells but usually do not actively secrete Igs. They exist in a quasi-quiescent state, with only m3% of the population in cell division. Patients with CLL often experience a suppression of immune responses and, in contradistinction, autoimmunity. An increased incidence of colon and skin cancers may be a reflection of depressed T cell immunity (12) (13) (14) (15) (16) . The abnormal immune functions observed in CLL may be mediated by products of the B cell 1 Abbreviation used in this paper: CLL, chronic lymphocytic leukemia. malignancy and, furthermore, may be a determining factor in the chronic nature of the disease.
A number of studies have suggested that growth factors and/or their receptors have a role in CLL. High concentrations of soluble IL2 receptors, for example, have been detected in the serum of CLL patients, and IL-1 production by CLL cells has been documented (17) (18) (19) (20) (21) (22) (23) . Other studies have suggested a role for TNF in supporting the proliferation of CLL cells (24, 25) . Another potential growth regulatory factor for CLL would be IL7 and/or IL-7 receptors. IL-7 is a stromal cell-derived growth factor for early lymphoid stem cells, including progenitor B and Pre-B cells, as well as for pre-T and cytotoxic cells (26) (27) (28) (29) (30) (31) . Our laboratory became interested in cytokine growth signals associated with leukemia cells when we found an IL-1 receptor-associated marker on CLL cells (32) (33) (34) . We postulated that a cytokine(s) and its receptor(s) might contribute significantly both to leukemic transformation and to the immune anomalies associated with CLL. Cytokines or cytokine receptors could also effect the chronic state of the leukemia by inducing nonleukemic immune cells to function in an abnormal manner. The question we first asked was whether endogenously produced cytokines and/or cytokine receptors might serve a role in the leukemic transformation of B cells. We approached the analysis of cytokine and cytokine receptor expression via the PCK (35) and included an examination of the expression of a variety of cytokines/cytokine receptors associated with B cell growth and differentiation. Flow cytometry was used to isolate mononuclear cell subsets, to examine expression of receptors for II:7, and then to phenotype I1:7 receptor-bearing cells. A portion of the data obtained is presented here and demonstrates that PBMC from CLL patients express I1:7 mKNA while cells from normal blood donors do not.
Materials and Methods
Cell Sources. Table 2 ). The data presented in this manuscript were obtained largely with I1-7 primers and include others only as necessary for controls to demonstrate that an experiment was a technical success. A more inclusive report with these as well as other primers will be published elsewhere. The primer set for the 11-2 receptors are for the p55, TAC, ce chain. Southern Hybridizations. Clonal rearrangement of leukemic Ig genes was examined in Southern hybridizations with the Jh probe, C76R51 (37) . DNA was isolated from total PBMC and from subsets sorted by flow cytometry, then cut with the restriction enzyme EcoKI. The DNA samples were separated overnight in a 0.7% TAE-buffered agarose gel, transferred to a nylon membrane, and probed with 32P-labeled C76R51 (38) .
Results

IL,7 raRNA Expression Was Detected by PCR in PBMC from CLL Patients but Not from Normal Donor Cells.
Cytokine expression was evaluated to determine whether a particular cytokine was consistently expressed in CLL patients' PBMC that was not expressed in normal individuals. Our data revealed that II,7 was expressed in ceils from 20 of 20 CLL patients tested ( Table 3 ). The I1--7 PCR product migrated in agarose gel electrophoresis to the approximate size predicted for an mRNA-derived template (681 bp; Fig The reverse and forward primers for Ib7 span five introns of genomic sequence, therefore, a PCK product derived from genomic DNA would be substantially larger (i.e., several kilobases). The data from these experiments revealed that mRNA for I1:7 indeed was expressed in cells from CLL patients. No I1:7 mRNA was detected in cells obtained from normal individuals (0/7) ( Table 3) . Positive PCR products, either I1:1fl, I1:2R, or both, demonstrated that the experiments were technical successes. One concern, however, was whether the difference in the ability to detect Ib7 mRNA was a reflection of the large numbers of CD5 + leukemic B cells present in CLL patients or was undetected because of the substantially smaller number of CD5 + B cells in normal individuals. Two approaches were used to resolve this issue. First, the minimal number of CLL cells required to detect I1:7 mRNA was determined. While a faint band for I1:7 was detected at low numbers of CLL cells (5 x 10 s and 1 x 10 6) (Fig. 2, lanes 4 and 7) , no IL-7 product was detected with high numbers of normal donor cells (107) (Fig. 2, lane   11 ). "CD5 + ,CD20 + cell equivalents" were calculated based on dual marker studies of these donors. Whereas an IL-7 PCR product was readily detected with ,,~1,300 "CD5 § ,CD20 § CLL cell equivalents" and actually could be observed at 650 "cell equivalents" (Fig. 2, lane 7) , no Ib7 PCR product was evident at ,~2,050 "CD5 + ,CD20 + normal cell equivalents" (Fig. 2, lane II) . IblB and IL2R PCR products were readily 7) . Cell equivalents were calculated to determine the maximum number of cells that contributed template for the 7/~1 of PCR product loaded into the gel based upon a theoretical yield of 100%. This number was used to calculate the minimum number of normal donor cells required to start with an equivalent number of CD5 + B cells. Normal donor cells at 10 x 106 represented greater than twice the minimum number of cell equivalents required (lanes 9-11). Lanes I and 8, 123-bp ladder; lanes 2-4, 0.5 x 106 CLL cells, PCR products of primers for Ibl/8, Ib6 receptor, and IL-7, respectively; lanes 5-7, 106 CLL cells, PCR products of primers for IL-lfl, IL-6 receptor, and I1-7, respectively; lanes 9-11, 10 x 106 normal donor cells, PCR products of primers for I1-1B, I1-2 receptor, and 11-7, respectively; lanes 12 and 13, 11-1fl PCR products from 106 and 0.5 x 10 6, respectively. detected with 107 normal ceils, while I L l 3 was also readily detected with 106 as well as 5 x 10 s normal cells (Fig. 2,   lanes 9, 10, 12, and 13, respectively) . The IL-lfl as well as I b 6 R primers also served as positive controls for the CLL R N A and cDNA preparations (Fig. 2, lanes 1 were used to isolate cell subsets with antibodies directed against either of the pan-B cell markers, CD19 or CD20, and the B cell subset marker, CD5. mAbs to CD20 were used with normal cells and the initial three CLL patients (nos. 1-3), while mAbs to CD19 were used more recently with the CLL cell preparations. CD5 also serves as a pan-T cell marker. Examination of T-depleted, B-enriched mononuclear cells from a normal donor revealed a density map profile of fluorescence expected from these two markers (Fig. 3 A) . The majority subset now consisted of single-positive CD20 + cells as seen in the upper left quadrant, while the second most prominent subpopulation was the double-negative, non-T, non-B cells observed in the lower left quadrant, and, a third, less prevalent subpopulation of residual CD5 + T cells was observed in the lower right of the contour map (Fig. 3 A) . The doublepositive CD5+,CD20 + cells were hardly discernible as a distinct subpopulation in the upper right quadrant. In contrast, most CLL patients had a majority subpopulation of CD5+,CD19+/20 § cells, as observed in the upper right quadrant (Fig. 3 B) . The proportion of T cells, CD5-B cells, and non-T, non-B cells observed varied with each patient. The double-positive CD5 +, CD19 +/20 + population in five of the CLL patients ranged from 25 to 93% with a median of 71%. The contrast between normal donor and the CD5 + leukemic patients as observed in Fig. 3, A and B, reflects the overwhelming contribution of the monoclonal leukemic population. 2 of 11 patients examined by dual-color analyses, however, had relatively few double-positive cells, but instead had a CDS-,CD19 + majority B cell subpopulation and evidently had the more rare form of C D 5 -CLL (Fig.  3 C) . Parameters were then set to isolate the normal CD5 +,CD20 + cells, the CLL patients' CD5 +,CD19 + or CD5-,CD19 + cells, as well as other selected subpopulations. Contour maps of the dual-labeled mononuclear cells from the three respective types of individuals before and after cell sorting are presented: normal (Fig. 4 A) , CD5 + CLL (Fig.  4 B) , and CD5-CLL (Fig. 4 C) . Each isolated subset was reexamined by flow cytometry and found to consist of >96% purified cells (Fig. 4, right) . The cells were then washed and processed for the isolation of R N A . Complementary D N A was synthesized, and P C R assays were performed. The P C R data demonstrated that the B cell subsets that contained the respective leukemic population expressed IL-7 m R N A (Table  4 and 5, lanes 4 and 7, respectively). Normal CD5 § B cells, however, did express IL-lfl, thereby demonstrating: r that the experiments were technically successful, and (b) t,,at the expression of IL-lfl is a normal function of CD5 + B cells (Fig.  5, lane 5) . The predominant C D 5 -, C D 2 0 + normal B cells also express IL-1B but to a lesser degree (Fig. 5, lane 7) . Equivalent levels of I b 6 R PCR products were detected in both subsets of B cells (Fig. 5, lanes 6 and 9) . I b 2 R expression was evident in both B cell subpopulations (38a). These data demonstrate, therefore, that the synthesis and secretion of IL-1/~ by CLL cells most likely is unrelated to their leukemic transformation. Expression of IIr however, is unique to cells from the CLL patients.
Other cell subsets from the CLL patients were also examined for expression of II. CLL nos. 1-3 were fractionated by flow cytometry sorting using the mAb Leu-16 directed against the B cell marker CD20. CLL nos. 10, 4, 11, and 16 were fractionated similarly using the mAb Leu-12 directed against the B cell marker CD19. cell fractions that yielded mKNA-derived IL-7 PCR products were the leukemic subsets from the CLL donors ( pressed IL-6R P C R products (Fig. 6, lanes 8 and 10) . The yield of P C R products obtained with positive control primers tested in the IL-7--sorted fractions, of either the CLL patients or the normal donors, were of levels comparable to those obtained with these primers in the IL-7 § fractions. Furthermore, the IL-7-cell fractions remained negative after increasing the volume of template in the PCK mixture by as much as 20-fold. The absence of detectable Ib7 P C R product, therefore, was most likely due to the absence of or substantially diminished levels of IL-7 m K N A .
Proof of Clonality of CLL Patients' Cells Using an Ig Heavy
Chain Marker, Jh Probe. Southern hybridizations revealed that leukemic cells purified by flow cytometry cell sorting exhibited clonality in that no germline genes and only rearranged genes were detected in the sorted fractions (Fig. 7 (Fig. 7, lane 2) , and only moderately detected in unsorted cells of five different leukemic patients (Fig. 7, lanes  3-7) . In fact, in patient CLL no. 2's total PBMC sample, few normal cells were detected as evidenced by the weakness of the germline band and the preponderance of the clonally rearranged band (Fig. 7, lane 4) . Analysis of flow cytometry-sorted cells revealed only clonally rearranged bands and no germline gene band in the CD5 +,CD19 § leukemic subset (Fig.  7, lane 8) . These data are consistent with previous studies demonstrating clonal Ig gene rearrangements in neoplastic B cells (39) (40) (41) .
IL-7 Receptors Are Expressed on CeUs from CLL Patients. If II,7 serves a function in CLL, then one would expect that CLL patients' cells would express receptors for I1,7. Fluorescent dye-tagged cytokines were used with flow cytometry to evaluate I1,7 binding and to characterize the cells that expressed 11,7 receptors. Positive binding of I1,7 was observed with cells from four of four CLL patients examined. The percentage of total cells that stained specifically for I1,7 receptors varied between the patients from 1.1 to 53.4%. Each patient also had a variable percentage of the leukemic subset of B cells ranging from 20 to 96%. The percentage of specific I1,7 receptor-bearing cells in a given patient, however, was reproducible with an average deviation from the mean in CLL no. 2 of 2.67% in three replicate binding studies. The binding of biotinylated I1,7 to cells from two patients (CLL nos. 2 and 5) but not to T-depleted normal donor cells (normal control) is depicted in Fig. 8 . CLL cells incubated with the Streptavidin-PE (Avidin-PE) reagent without biotinylated IL-7 served as the control for nonspecific reagent binding, and their fluorescence curve was superimposable over the normal T-depleted donor curve, demonstrating no evidence of binding. The specificity of I1,7 binding was evaluated with recombinant, unlabeled I1,7 incubated at a 100-fold greater molar concentration than I1,7-PE. An inhibition of I1,7-PE binding demonstrated the specificity of I1,7 binding to its receptors (Fig. 9 B) . Approximately 53% of this CLL patient's cells specifically bound I1,7-PE (Fig. 9 C) . Ib7 receptor-positive cells were surface phenotyped using anti-CD5 conjugated with 
D i s c u s s i o n
We have demonstrated that mRNA for the cytokine I1,7 is expressed in cells from the leukemic subset of PBMC of patients with CLL. Normal B cells do not make detectable quantities of 11,7 mRNA. I1,7 serves as a progenitor lymphoid cell growth factor normally produced by stromal cells; thus, one possible role of I1,7 in CLL may be to serve as an autocrine or paracrine growth signal for the proliferating subset of B-CLL cells. Recent studies have suggested that I1,-7 can trigger proliferation in a variety of leukemic cells, Figure 8 . Flow cytometry analysis of PE-streptavidin-biotin-conjugated I1:7 bound to cells from two CLL patients, CLL no. 2 (black lines) and CLL no. 5 (gray lines), but not to normal T-depleted PBL (filled area). CLL cells incubated with PE-streptavidin but without biotinylated IL-7 are indicated as the hatched lines over the solid peak. (42) . It has also been shown that IL-7 serves as a signal for the induction of cytotoxic T and NK cells (47) (48) (49) (50) . These studies suggest that IL-7 can serve as a potent inducer of antitumor cytotoxic cells. Tumor cell-derived IL-7 in CLL could be triggering IL-7 receptors on nonleukemic cells and inducing such cell-mediated antitumor immunity, thereby resulting in the diminution of the disease with a prolongation of the leukemic course. The fact that IL-7 expression was only detected in cells obtained from leukemic patients and not from normal donors suggests that II.-7 mRNA expression may be related to the leukemic transformation of these B cells (Table 3) . Enriched normal CD5+,CD20 + B cells gave no evidence for IL-7 expression, but, IL-2 receptor expression was readily detected (Table 5 ). The normal majority B cell subset, CDS-,CD20 + , also expressed IL2 receptor but did not express IL-7 (Fig. 5, lanes 2 and 3) . It had been suggested that Ibl~ expression by CLL cells was related to their leukemic transformation (18) (19) (20) . Our PCR data with normal B cells refute that hypothesis and indicate that IL-1B expression occurs as a natural event in B cells (Fig. 5, lane 5) . The most compelling evidence, however, that II.-7 mRNA expression is related to leukemic transformation stems from our studies with fractionated cells from CD5 § vs. CD5-CLL patients (Fig. 6 ). In the CD5-CLL patient, an Ib7 PCR product was readily detected in the leukemic cell subset, CDS-,CD19 + (Fig. 6, lane 6 ). Yet, in the CD5 + patient, an I1.-7 PCR product was not detected in the same nonleukemic "normal subset," CD5-,CD19 + (Fig. 6, lane 4) , but, again, was detected in the leukemic cell subset, CD5 § ,CD19 + (Fig. 6, lane 2) . These data strongly support the suggestion that the expression of ILo7 may be associated with the leukemic transformation of B cells.
Our findings with II.-7 differ from murine lymphoma studies in that all human patients tested to date yield positive IL-7 PCR products with reverse-transcribed total RNA prepared from their cells (Table 3) , while no II.-7 PCR product was detected in the mouse cells (51) . The reasons for these differences are unclear. The primer sets used in each study were quite different. The Ib7 primer sets used in our studies spanned six exons, with the 5' end of the PCR product beginning at the ATG initiation codon for the first amino acid of the signal sequence and ending subsequent to the coding sequence in the 3' noncoding region (52) . The 681-bp IL-7 PCR product, therefore, contained the entire coding sequence for the IL-7 precursor protein. The primer set for Ib7 used in the murine lymphoma study began and ended in the 3' noncoding region of the cDNA sequence. Perhaps the differences in the primer sets used in the two studies could account for the dissimilar results observed, or perhaps stability problems for the IL-7 mRNAs occurred with the murine lymphoma cells.
In the Ib7 PCR products from CLL cells, a second, smaller, minor band was generally also evident at "~550 bp, as observed in Figs. 1, 2 , 5, and 6. This second band represents a PCR product derived from an alternatively spliced cDNA. The isolation of the original cDNA clones for human IL-7 revealed a deletion in one of the cDNA clones that was found to be due to alternative splicing (27) . The alternative transcript lacked the entire exon 4, which encodes 44 amino acids, thereby reducing the transcript size by 132 nucleotides. This size reduction corresponds precisely with the size of the second IL-7 PCR product band observed in our gels. The PVUII restriction site of this alternatively spliced II.,7 transcript remains intact (27, 52) . Upon PVUII digestion of our IL-7 PCR products, both the major and minor bands virtually disappeared and only the two expected digestion product bands were obtained, as observed in Fig. 1 . One of the restriction products of the alternatively spliced, minor band is identical with the 302-bp band of the major IL-7 band's restriction product and should merge with it, thereby appearing as a more dense band than that of the larger 379-bp band, as observed in Fig. 1, lane 3 . The second PVUII digestion product of the minor IL-7 PCR product should be '~247-bp and does not appear as a distinct third band in the figures presented here, but a diffuse band at the second marker band (246 bp) has been observed in gels where the undigested sample demonstrates a more dense alternate spliced product. The significance of the alternatively spliced transcript remains unknown. Our ability to detect both the entire intact coding sequence for IL-7 and an alternative spliced transcript that had been defined through molecular cloning lends further credence to our conclusions that CLL cells transcribe ILo7 mRNA. The regulation of expression of Ib7 in CLL as well as a determination of its function in the disease state remain as questions that need to be answered and are major areas of experimentation in our laboratory.
Our data suggest that within a given patient only a proportion of the CLL cells express Ib7 receptors and that other peripheral mononuclear cells, including some T cells and some non-T, non-B cells, also express IL-7 receptors. As has been the case for many of the cytokines, IL-7 has now been shown to have effects on a broader variety of cells than initially described, hence, IL-7 could also be effecting the T cell defects observed in CLL patients. Besides the possible role of I1.-7 in autocrine signaling of CLL growth and/or differentiation, it is also possible that IL-7 may directly trigger the diseaseassociated immunological aberrations in CLL.
